FMP
Brickell Biotech, Inc.
BBI
NASDAQ
Inactive Equity
Brickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.
2.35 USD
0.049999952 (2.13%)
About
ceo
Mr. Robert Brown
sector
Healthcare
industry
Biotechnology
website
https://www.brickellbio.comexchange
NASDAQ
Description
Brickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Car...
CIK
0000819050
ISIN
US10802T1051
CUSIP
10802T105
Address
5777 Central Ave Ste 102
Phone
17205054755
Country
US
Employee
16
IPO Date
Mar 10, 1993
Summary
CIK
0000819050
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
10802T105
ISIN
US10802T1051
Country
US
Price
2.35
Beta
0.08
Volume Avg.
0
Market Cap
7.08M
Shares
-
52-Week
-
DCF
2.69
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-5.6
P/B
-
Website
https://www.brickellbio.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest BBI News
It looks like there's no news available.
